Echo IQ

Sydney, Australia  All Australia companies → — Founded 2010
Imaging AI Specialist Specialty-Focused AI
Cardiology Cardiothoracic Surgery
Cardiology AI Clinical Decision Support & Reference
Public Company (ASX: EIQ, OTCQB: ECHQF) — A$24.4 million (plus US$150,000)
Website Claim this company

Products

EchoSolv AS
Echo IQ
Cardiology AI
EchoSolv AS is an FDA-cleared, AI-powered clinical decision support platform by Echo IQ that analyzes echocardiograms to identify patients at risk for severe aortic stenosis with high accuracy and efficiency, integrating into existing workflows.

See all 1 product →

About Echo IQ

Echo IQ is an Australian AI medical technology company dedicated to enhancing cardiovascular diagnostics through its proprietary AI-driven platform, EchoSolv. This platform is designed to provide physicians with rapid, precise insights into structural heart disease risk, primarily focusing on conditions such as Aortic Stenosis (AS) and Heart Failure (HF). Leveraging advanced machine learning and phenotype-based algorithms, EchoSolv analyzes echocardiographic data, drawing from one of the world’s largest datasets linked to mortality outcomes. This approach aims to significantly reduce misdiagnosis rates, improve the efficiency of clinical workflows, and facilitate more informed care planning by offering consistent, unbiased, and guideline-based detection of severe cardiac conditions.

The company’s flagship product, EchoSolv AS, received U.S. FDA 510(k) clearance in October 2024 and has demonstrated exceptional accuracy in detecting severe AS, often outperforming traditional human interpretation in rigorous validation studies. EchoSolv is engineered for seamless integration into existing clinical environments, processing data directly from echocardiogram reports without requiring raw image access or specialized hardware. Echo IQ is actively expanding its commercialization efforts for EchoSolv AS in the U.S. market through strategic partnerships with major hospital groups and leading imaging software providers, including a collaboration with the Mayo Clinic. Furthermore, the company is developing EchoSolv HF for Heart Failure, with anticipated FDA clearance in Q4 2025. By identifying high-risk patients who might otherwise be missed by conventional clinical guidelines, Echo IQ’s technology supports earlier intervention and ultimately aims to improve patient outcomes.

What Physicians Need to Know

Specialization
Echo IQ specializes in AI-driven solutions for cardiology, focusing on enhancing the diagnosis and assessment of severe structural heart diseases. Their flagship product, EchoSolv, targets conditions like Aortic Stenosis (AS) and Heart Failure (HF), with development underway for Pulmonary Hypertension (PH).
Key Differentiators
Echo IQ stands out due to its focus on specific, underdiagnosed structural heart diseases, ease-of-use, and universal integration capabilities. Their AI is built on the world's largest echocardiographic dataset linked to mortality, providing robust real-world validation. EchoSolv-AS is FDA 510(k) cleared and demonstrates near-perfect accuracy in detecting severe AS, outperforming traditional clinical interpretation. The technology is designed to be unbiased, excluding common clinical biases, and delivers results in seconds.
Technology Stack
Echo IQ leverages advanced AI and proprietary algorithms, including machine learning and phenotype-based algorithms. Their platform utilizes deep learning and is designed for seamless integration into existing clinical workflows, including DICOM stacks, to provide measurement-based decision support without requiring raw image analysis.
Physician Tip

For physicians, Echo IQ's solutions, particularly EchoSolv, offer significant advantages by enhancing diagnostic accuracy and reliability, leading to earlier detection of critical structural heart diseases. This facilitates timely intervention and ultimately improves patient outcomes by reducing missed diagnoses. The system is designed to seamlessly integrate into existing workflows with minimal disruption, providing rapid, real-time insights (under 3 seconds) at the point of clinical decision. Its unbiased assessment helps standardize care and can improve diagnostic confidence across varying skill levels, complementing clinician review and supporting value-based care initiatives.

Echo IQ's solutions are designed for seamless integration into existing clinical workflows and can connect with leading imaging software providers and large hospital networks. EchoSolv integrates with PACS systems without requiring EMR integration and has established partnerships, such as with ScImage's PICOM365 platform, and has been deployed in major institutions like Beth Israel Deaconess Medical Center. The commercial pathway is built to leverage existing diagnostic infrastructure within hospitals.

Products by Echo IQ

1 product in the directory

EchoSolv AS
Echo IQ
Cardiology AI
EchoSolv AS is an FDA-cleared, AI-powered clinical decision support platform by Echo IQ that analyzes echocardiograms to identify patients at risk for severe aortic stenosis with high accuracy and efficiency, integrating into existing workflows.

What the Web Says

Echo IQ is an Australian medical technology company specializing in AI-driven solutions for cardiology, primarily focusing on its EchoSolv platform. The company's main product, EchoSolv, is an AI-powered clinical decision support platform that analyzes echocardiograms to identify patients at risk for structural heart diseases like aortic stenosis and heart failure. Echo IQ has secured FDA approval for its aortic stenosis detection tool, and a second product for heart failure is currently under FDA review. The company has also established partnerships with major healthcare institutions like the Mayo Clinic and Mount Sinai Health System.

Overall: Mixed

Strengths

  • AI-powered platform for early and accurate detection of structural heart diseases.
  • FDA clearance for aortic stenosis detection tool.
  • High sensitivity (99.5%) in detecting heart failure in studies.
  • Integrates with existing PACS systems without requiring EMR integration.
  • Partnerships with leading healthcare institutions like Mayo Clinic and Mount Sinai.
  • Potential for significant growth in a large market.

Limitations

  • Currently a pre-revenue company with negligible revenue and deep annual losses.
  • Single-product focus (EchoSolv) creates reliance on its success.
  • Success is dependent on commercial adoption of unproven software.
  • Faces intense competition from established MedTech giants.
  • Reliance on external funding and a history of diluting shareholder value.
  • FDA clearance for EchoSolv HF is not guaranteed and timing is uncertain.

Based on reviews from: Elion, KoalaGains, Reddit, Intelligent Investor, DAIC, YouTube, Simply Wall St, Evolution Capital, Stocks Down Under

Last updated: 2026-07-17

Videos

News, demos, and interviews about Echo IQ.

Loading videos...

Videos load interactively. If none appear, search YouTube for Echo IQ →

View all on YouTube

Press & Coverage

TipRanks.com
Echo IQ raises A$110m to accelerate U.S. push and expand cardiovascular AI platform
Echo IQ has secured A$110 million in an institutional placement to fund its U.S. commercial expansion of the EchoSolv platform and accelerate the development of its broader cardiovascular AI portfolio. This funding follows recent milestones including FDA clearance for EchoSolv for aortic stenosis and strategic partnerships.
2026-06
HLTH
Echo IQ Secures FDA Approval for AI Heart Disease Diagnosis Tool - HLTH
Echo IQ received U.S. FDA 510(k) clearance for its AI-based solution, EchoSolv AS, which aids in diagnosing severe aortic stenosis. The company is now focusing on U.S. commercialization, including partnership discussions with hospital groups and pursuing licensing opportunities.
2024-10
GlobeNewswire
Echo IQ Announces EchoSolv AS Deployed into Mount Sinai Health System
Echo IQ has deployed its AI-based decision support software, EchoSolv AS, with Mount Sinai Health System in New York, USA. This deployment is a significant step in the company's U.S. commercial growth and aims to support cardiologists in assessing severe aortic stenosis.
2026-04
GlobeNewswire
EchoIQ Strengthens Leadership Team and Clinical Advisory Network to Accelerate Next Phase of Commercial Growth and U.S. FDA Initiatives
Echo IQ announced the appointment of Matthew Dodds as Chief Financial Officer and Dr. Vinod Thourani as Clinical Advisor to bolster its leadership and clinical network. These appointments aim to support the company's commercial growth, U.S. market expansion, and FDA initiatives for its EchoSolv platform.
2026-06
MarketScreener
Echo IQ Enters Collaboration With Mayo Clinic to Evaluate AI-Based Cardiac Risk Stratification in Cancer Patients
Echo IQ has partnered with Mayo Clinic to research the use of its AI platform for cardiac risk stratification in oncology patients. The study will assess if echocardiographic data can generate predictive heart failure risk scores for cancer patients undergoing therapy.
2026-06
PR Newswire
ECHO IQ SIGNS STRATEGIC PARTNERSHIP AND INTEGRATION AGREEMENTS WITH SCIMAGE AND MEDAXIOM TO EXPAND ECHOSOLV AS ACROSS 36 US CARDIOLOGY NETWORKS
Echo IQ has signed strategic partnership and integration agreements with ScImage and MedAxiom to significantly expand the distribution of its EchoSolv AS technology across 36 U.S. cardiology networks. This collaboration will integrate EchoSolv AS into ScImage's medical workflow platform.
2025-04
Echo IQ Investors
Exclusive Imaging Dataset Strengthens AI Competitive Moat
Echo IQ secured an exclusive data licensing agreement with Advara HeartCare, Australia's largest private cardiovascular provider. This agreement grants Echo IQ access to a substantial number of de-identified echocardiography studies to further train its next generation of AI.
2026-07
PMC
An Artificial Intelligence Algorithm for Detection of Severe Aortic Stenosis: A Clinical Cohort Study - PMC
A clinical cohort study, supported by Echo IQ Pty Ltd, demonstrated that an AI-DSA (AI-driven decision support algorithm) reliably identified the phenotype of severe aortic stenosis using echocardiographic reports, without relying on left ventricular outflow tract measurements. The study suggests the potential utility of this AI-DSA to enhance the detection of severe AS.
2024-09

Frequently Asked Questions

Echo IQ's flagship product, EchoSolv, primarily focuses on detecting structural heart diseases. Currently, EchoSolv AS is FDA-cleared for identifying severe Aortic Stenosis, and EchoSolv HF is undergoing the FDA approval process for Heart Failure detection.
Echo IQ prioritizes data security and privacy, having achieved SOC 2 Type 1 and HIPAA compliance. This ensures their handling of sensitive health information meets stringent industry standards for secure operations and data protection.
Echo IQ utilizes a subscription-based model, with compensation anticipated per scan. The company is actively working to secure Category I and Category III CPT codes for reimbursement in the US, with an estimated revenue share of $20-$25 USD per use for aortic stenosis.
Echo IQ's solutions are designed for minimal disruption and seamless integration into existing clinical workflows, analyzing data from echocardiogram reports without needing raw image access. While specific support details are on their website, their partnerships with imaging platforms like ScImage suggest integrated support for deployment.
Echo IQ has established significant partnerships with key healthcare entities such as MedAxiom, ScImage, and the Mayo Clinic. These collaborations are crucial for expanding the distribution of their AI solutions and integrating them into extensive hospital and cardiology networks across the US.
Echo IQ demonstrates strong financial stability, having recently secured A$17.3 million in an institutional placement to fund its US expansion and technology development. As a publicly listed company (ASX: EIQ) with a market capitalization of approximately $404.81 million, it reflects investor confidence in its growth trajectory.

Comparisons

EchoSolv AS vs EchoNext
EchoSolv AS vs PMcardio
EchoSolv AS vs KardiaPro
Acumen Hypotension Prediction Index – EV1000 Clinical Platform vs EchoSolv AS

Related Companies

CAIMed (Niedersächsisches Zentrum für KI und Kausale Methoden in der Medizin)
Hannover, Germany (Lower Saxony region)

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm
Berkeley, United States and London, United Kingdom. European office in Barcelona, Spain and Gothenburg, Sweden.

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA
London, UK

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Fraunhofer-Gesellschaft (Fraunhofer AICOS) / PALMX APPS LTD / Skin Analytics
London, United Kingdom

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI
Canberra, ACT, Australia

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART
Boizenburg / Elbe, Germany

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]
Suggest an Edit →
AI Tool Finder
AI-powered search. Results may not be comprehensive.